A Study of Sitravatinib in Combination with Nivolumab vs Docetaxel in Patients with Advanced Nonsquamous Nonsmall Cell Lung Cancer with Disease Progression on or after Platinum Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy(MRT516005)
A Study of Sitravatinib in Combination with Nivolumab vs Docetaxel in Patients with Advanced Nonsquamous Nonsmall Cell Lung Cancer with Disease Progression on or after Platinum Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy(MRT516005)
Trial Category:
Lung
Phase
III
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE